Global Equity International Inc. is a global business advisor that provides capital raising, strategic planning, and management placement services to small and mid-sized companies. It generates revenue through cash payments and equity success fees from its portfolio of over 18 client companies across various sectors and geographies. The company has an established 8-year operating history and reported $2.4 million in revenue and $700k in net income over the past 12 months. It aims to expand its deal pipeline and pursue value-added acquisitions to drive continued growth. Global Equity International is led by an experienced management team and seeks to up-list its shares to a senior stock exchange.
In 2013, the ban on general solicitation of accredited investors was lifted, causing the largest change to securities laws in decades. While everyone from startups to hedge funds will enjoy new liberties in investor marketing and outreach campaigns, it’s critical that the new rules are followed to a T, eliminating the chance for exemption rescission.
Prologis Presentation - Citi 2016 Global Property CEO ConferenceMary Taylor
Prologis, Inc. (NYSE: PLD), the global leader in industrial real estate, presented at the Citi 2016 Global Property CEO Conference on March 15. CEO Hamid R. Moghadam gave a company overview, including discussion of market conditions and the company's future outlook. He was joined by Thomas Olinger, chief financial officer, and Michael Curless, chief investment officer. http://ir.prologis.com/
This document brings together a set
of latest data points and publicly
available information relevant for
Financial Services Industry. We are
very excited to share this content and
believe that readers will benefit from
this periodic publication immensely.
NETSOL Technologies is a global fintech and IT company with domain expertise in leasing and financing industries. The Company's suite of applications are backed by 40 years of domain expertise and supported by a committed team of 1300+ professionals placed in eight strategically located support and delivery centers throughout the world.
This document brings together a set
of latest data points and publicly
available information relevant for
Financial Services Industry. We are
very excited to share this content and
believe that readers will benefit from
this periodic publication immensely.
In 2013, the ban on general solicitation of accredited investors was lifted, causing the largest change to securities laws in decades. While everyone from startups to hedge funds will enjoy new liberties in investor marketing and outreach campaigns, it’s critical that the new rules are followed to a T, eliminating the chance for exemption rescission.
Prologis Presentation - Citi 2016 Global Property CEO ConferenceMary Taylor
Prologis, Inc. (NYSE: PLD), the global leader in industrial real estate, presented at the Citi 2016 Global Property CEO Conference on March 15. CEO Hamid R. Moghadam gave a company overview, including discussion of market conditions and the company's future outlook. He was joined by Thomas Olinger, chief financial officer, and Michael Curless, chief investment officer. http://ir.prologis.com/
This document brings together a set
of latest data points and publicly
available information relevant for
Financial Services Industry. We are
very excited to share this content and
believe that readers will benefit from
this periodic publication immensely.
NETSOL Technologies is a global fintech and IT company with domain expertise in leasing and financing industries. The Company's suite of applications are backed by 40 years of domain expertise and supported by a committed team of 1300+ professionals placed in eight strategically located support and delivery centers throughout the world.
This document brings together a set
of latest data points and publicly
available information relevant for
Financial Services Industry. We are
very excited to share this content and
believe that readers will benefit from
this periodic publication immensely.
Highlights of the fourth quarter of 2010. Net sales amounted to SEK 27,556m (28,215) and income for the period was SEK 677m (664), or SEK 2.38 (2.34) per share. Net sales increased by 1.6% in comparable currencies.
Für die empirische Untersuchung „Mittelstandskommunikation 2016 – Studie zur Professionalisierung, Digitalisierung und Führung der Unternehmenskommunikation“ wurden im Frühjahr 2016 insgesamt 561 Unternehmen in Deutschland befragt, darunter 270 Entscheider aus mittelständischen Unternehmen. Die Studie illustriert den Status quo der Kommunikation in konzernunabhängigen Unternehmen mit maximal 499 Mitarbeitern und einem Umsatz von bis zu 50 Mio. Euro. Das Gemeinschaftsprojekt der Universität Leipzig mit Fink & Fuchs und dem Magazin pressesprecher schließt an die Vorgängerstudie von 2015 an.
Unternehmenskommunikation im Mittelstand wird zunehmend professioneller und digitaler. Aber es fehlen nach wie vor oft klare Kommunikations- und Digitalisierungsstrategien, übergreifende Kommunikationsziele und fachkundige Kommunikationsabteilungen. Zudem behindert die kommunikative Zurückhaltung vieler Unternehmer oft die notwendige Weiterentwicklung in Marketing und Public Relations.
Der 89-seitige Ergebnisbericht ist hier verfügbar. Weitere Informationen finden sich unter www.mittelstandskommunikation.com sowie www.communicationmanagement.de in der Rubrik "Mittelstandskommunikation".
Document Security Systems (DSS) is a multinational company operating businesses focused
on brand protection technology, blockchain security, direct marketing, healthcare, real estate,
and securitized digital assets. Its business model is based on a distribution sharing system in
which shareholders will receive shares in its subsidiaries as DSS strategically spins them out
into IPOs. Its historic business revolves around counterfeit deterrent and authentication
technologies, smart packaging, and consumer product engagement. DSS is led by its seasoned
leaders with decades of industry experience.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
INNO HOLDINGS INC. is an innovative building-technology company with a mission to transform the construction industry with our proprietary cold-formed steel- framing technology and other building innovations
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
2. This presentation may include forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements related
to anticipated revenues, expenses, earnings, operating cash flows, the outlook for
markets and the demand for products. Forward-looking statements are no
guarantees of future performance and are inherently subject to uncertainties and
other factors which could cause actual results to differ materially from the
forward-looking statements. Such statements are based upon, among other
things, assumptions made by, and information currently available to,
management, including management's own knowledge and assessment of the
Company's industry and competition. The Company refers interested persons to
its most recent Annual Report on Form 10-K and its other SEC filings for a
description of additional uncertainties and factors, which may affect forward-
looking statements. The company assumes no duty to update its forward-looking
statements.
Safe Harbor Statement
2Global Equity International Inc. | OTCQB: GEQU
3. Corporate Overview
3Global Equity International Inc. | OTCQB: GEQU
“Helping Build Great Companies”
Global Equity International Inc.
Global Equity Partners Plc. GEP Equity Holdings Limited
US Holding Company
non-US Operating Subsidiaries
Global Business Advisor – Capital raising, strategic planning,
management placement, and more; targeting small- to mid-
sized companies.
Diverse, sector agnostic portfolio of 18+ client companies;
generates cash payments and equity success fees.
Significant relationships in US, United Kingdom, Central
Europe, the Middle East, and South East Asia.
Offices in Dubai and London.
GE Professionals DMCC
4. Key Facts
4Global Equity International Inc. | OTCQB: GEQU
Exchange: Ticker OTCQB: GEQU
Recent Price $0.015
Market Cap $5.55 million
Shares Outstanding 370 million
Float 211 million
Revenue (ttm) $2.4 million
Fiscal Year December 31
5. Investment Highlights
5Global Equity International Inc. | OTCQB: GEQU
Established Business; 8-year operating history
Revenue: $2.4 million (ttm); net income: $700K (ttm).
Shareholders´ Equity up 200%+ in first nine months of
2016.
Diverse portfolio of 18+ client companies (equity positions);
multiple late-stage projects - Attractive exit opportunities via
public listings.
Potent Financial Partners around the Globe.
Seasoned and experienced management team.
Plans to up-list to Senior Exchange.
6. Business Strategy & Model
6Global Equity International Inc. | OTCQB: GEQU
Multi-Pronged Growth Strategy
- Expanding deal flow pipeline; up 36% in 2016.
- Leveraging relationships with third-parties.
- Seeking value-added acquisitions around the globe.
GEQU takes equity ownership stake in clients.
Additional revenue generated from cash retainers
and cash success fees for milestone achievements.
Recurring fees from Dubai based HR division –
“Kingsman James”.
Model:
7. Key Client Opportunities
7Global Equity International Inc. | OTCQB: GEQU
Leading Financial Technology solutions
provider.
Blue-chip clients.
$2M private placement completed (4Q16).
Hotel project in Cyprus.
$301.5M term sheet (3Q16).
Potential $11M+ success fee (shared with JV
partner).
Clean energy company.
Patented heat conversion technology.
May provide up to $35M funding.
Majestic
Wealth Ltd.
Granite
Power
8. Financial Highlights
8Global Equity International Inc. | OTCQB: GEQU
$3.3
-$3
-$2
-$1
$0
$1
$2
$3
$4
2013 2014 2015
REVENUE
(in millions)
Revenue Net Income
M
9. Management
9Global Equity International Inc. | OTCQB: GEQU
Peter Smith - Director & CEO
Peter has been involved in the finance industry since 1986 when he passed his stockbroking examinations for the
London Stock Exchange aged 18. He has previously been an option trader, gilts trader, private client stockbroker
before he built a global financial services company between 1993 and 2006 resulting in $2.2bn under management
and 300 + staff. As the founder of Global Equity International he recognized a gap in the market for assisting small to
medium sized companies achieve their goals and ambitions by bringing together a network of professionals to help
the clients of the company on a cost effective, majority sweat equity model.
Enzo Taddei - Director & CFO
Enzo holds a degree in Economics from EADE University in Malaga (Spain) and also a Bachelor in Business
Administration (BBA) from the University of Wales. He also holds a “Masters Degree” in Spanish and International
Taxation granted to him by EADE University in Malaga (Spain) in 2000. Fluent in three languages and a specialist in a
broad range of accounting and also taxation procedures and disciplines, he leads the finance team of Global Equity
International and assists most clients on financial matters. Enzo also has extensive experience of public companies in a
number of jurisdictions and is an expert on structure and planning for the maximum effect.
Patrick Dolan - Managing Director (UK)
Patrick Dolan was senior figure in the software and technology market in a 20 year plus career he has held numerous
senior management positions within large and small startup enterprises in the US, Asia Pacific and in Europe. Patrick
has had extensive experience in managing large global operations with enterprises such as Standard & Poors, Dow
Jones, Citibank, State Street and more recently Merchant Capital. In the last 12 years he has worked within the
technology and software sector in small to medium sized companies expanding them operationally and exiting through
either the public markets or through trade sales. Patrick brings a lot of experience from both an operational and capital
raising perspective and has significant contacts across the financial markets.
10. Investment Highlights
10Global Equity International Inc. | OTCQB: GEQU
Growth Value Proposition.
Solid Revenues.
Shareholders´ Equity up 200%+ in 9 months of 2016.
Seasoned and Experienced Management Team.
Plans to up-list to Senior Exchange.
Major Revenue Acquisition Plan in early stages.
Development of “Special Opportunities Fund”.
A Full Service Firm.
11. OTCQB: GEQU
Global Equity International, Inc.
X3 Jumeirah Lake Towers
Office 3305
Dubai
United Arab Emirates
Tel: + 971 42 767 576
http://www.gepartnersplc.com/
http://globalequityinternational.com/